Pyxis Oncology (PYXS) Stock Analysis & AI Equity Report
Pyxis Oncology (PYXS) overview
Pyxis Oncology (PYXS) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 13.9m and operating profit of USD -84.4m; the year-end share price was 1.15 USD and market capitalisation was USD 72.1m. Pyxis Oncology is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Pyxis Oncology's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Pyxis Oncology
Pyxis Oncology is a clinical-stage company developing treatments for solid tumors, with an immediate focus on head and neck squamous cell carcinoma. Its lead investigational candidate, micvotabart pelidotin, is an antibody-drug conjugate designed to target a fibronectin variant in the tumor microenvironment and deliver a drug payload. The candidate is being studied alone and in combination with pembrolizumab.
Generate the Pyxis Oncology report
Pyxis Oncology is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Pyxis Oncology and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Pyxis Oncology
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.